| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Specific molecular targets of Pratensein-7-O-β-D-glucopyranoside have not been extensively characterized. As an isoflavone glycoside, it may share biological activities with other isoflavones, including estrogenic or anti-estrogenic effects through interaction with estrogen receptors. It may also exhibit antioxidant, anti-inflammatory, or other bioactive properties. However, specific molecular targets have not been identified in the available literature.
|
|---|---|
| ln Vitro |
In vitro, Pratensein-7-O-β-D-glucopyranoside is a new isoflavone. As an isoflavone glycoside, it may exhibit antioxidant properties. It has been reported in Hippophae rhamnoides, Astragalus membranaceus, and other organisms. However, detailed in vitro activity data including IC₅₀ values have not been extensively published. Further studies are needed to characterize its biological activities.
|
| ln Vivo |
In vivo activity data for Pratensein-7-O-β-D-glucopyranoside are not available in the published literature. The compound has been primarily characterized as a natural product from Fabaceae plants. No in vivo pharmacological studies have been reported for this compound. Further research is needed to evaluate its potential biological activities in animal models.
|
| Enzyme Assay |
In vitro assays for Pratensein-7-O-β-D-glucopyranoside are not extensively documented. As an isoflavone glycoside, potential assays could include antioxidant activity evaluation using DPPH or ABTS radical scavenging assays, estrogen receptor binding assays, or anti-inflammatory activity by measuring cytokine production in immune cells. The compound's structure can be confirmed by NMR and MS. Purity is typically assessed by HPLC.
|
| Cell Assay |
In vitro cellular assays for Pratensein-7-O-β-D-glucopyranoside are not extensively documented. Potential cellular assays could include evaluation of estrogenic activity in estrogen receptor-expressing cell lines, antioxidant activity in cell-based oxidative stress models, or anti-inflammatory activity in immune cells. Cells are treated with the compound and cell viability, receptor activation, or cytokine production is measured.
|
| Animal Protocol |
In vivo animal experiments for Pratensein-7-O-β-D-glucopyranoside have not been reported in the published literature. The compound has been studied primarily as a natural product from Fabaceae plants. No animal studies have been conducted to evaluate its pharmacological effects, toxicity, or pharmacokinetics. Further research would be required to investigate its potential therapeutic applications in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Pratensein-7-O-β-D-glucopyranoside have not been characterized. The compound has a molecular weight of 462.40 g/mol and a molecular formula of C₂₂H₂₂O₁₁. As a glycosylated isoflavone, it is expected to have limited oral bioavailability due to its hydrophilic sugar moiety. The compound may undergo deglycosylation in the gastrointestinal tract to release the aglycone for absorption.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Pratensein-7-O-β-D-glucopyranoside has not been extensively documented. As a naturally occurring isoflavone glycoside from Fabaceae plants, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
According to reports, pratenin 7-O-glucopyranoside has been found in Hippophae rhamnoides, Astragalus membranaceus, and other organisms with available data.
Pratensein-7-O-β-D-glucopyranoside (CAS# 36191-03-4, molecular formula C₂₂H₂₂O₁₁, molecular weight 462.40) is a naturally occurring isoflavone glycoside from Fabaceae plants such as Trifolium pratense. Also known as a new isoflavone. No clinical trials or regulatory approvals have been identified. |
| Molecular Formula |
C22H22O11
|
|---|---|
| Molecular Weight |
462.403
|
| Exact Mass |
462.116
|
| CAS # |
36191-03-4
|
| PubChem CID |
16202157
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.8
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
729
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=C(C=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O
|
| InChi Key |
FGAAKLDKKBMYCB-RECXWPGBSA-N
|
| InChi Code |
InChI=1S/C22H22O11/c1-30-14-3-2-9(4-12(14)24)11-8-31-15-6-10(5-13(25)17(15)18(11)26)32-22-21(29)20(28)19(27)16(7-23)33-22/h2-6,8,16,19-25,27-29H,7H2,1H3/t16-,19-,20+,21-,22-/m1/s1
|
| Chemical Name |
5-hydroxy-3-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1626 mL | 10.8131 mL | 21.6263 mL | |
| 5 mM | 0.4325 mL | 2.1626 mL | 4.3253 mL | |
| 10 mM | 0.2163 mL | 1.0813 mL | 2.1626 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
